Last reviewed · How we verify
Congenital atresia of the pulmonary valve
Approved treatments
- Caverject · Pfizer
- Prostavasin · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital atresia of the pulmonary valve patent landscape — cliff calendar, originator estates, attackable patents
- Congenital atresia of the pulmonary valve treatment landscape brief
- Congenital atresia of the pulmonary valve treatment updates RSS
Frequently asked questions about Congenital atresia of the pulmonary valve
What drugs treat Congenital atresia of the pulmonary valve?
Tracked treatments include Caverject, Prostavasin.
What is the treatment for Congenital atresia of the pulmonary valve?
Standard treatment for Congenital atresia of the pulmonary valve includes Caverject, Prostavasin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Congenital atresia of the pulmonary valve patent cliff · Congenital atresia of the pulmonary valve CI report
- Treatment: Caverject · Pfizer
- Treatment: Prostavasin · Hannover Medical School
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing